ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial Immune Response to Influenza Vaccine in Subjects with B-cell Malignancies Treated with Idelalisib
EudraCT number 2017-003055-30
Protocol number GS-US-313-4100
Sponsor Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States of America
Indications Hemato-oncology
Diagnosis Influenza Vaccine / Idelalisib
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2018
Date of approval by Institute (SÚKL) 13..6.2018
Date of approval by EC 6.6.2018
Date of initiation CT in ČR 27.12.2018
Date of ending CT in ČR 23.10.2019
Sites Fakultní nemocnice v Motole,Onkologická klinika,V Úvalu 84,Praha 5-Motol,150 06
Fakultní nemocnice Královské Vinohrady,Interní hematologická klinika,Šrobárova 1150/50,Praha 10,100 34

‹‹ Back to list